Anand A

Department of Psychiatry and Psychology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.

5 papers · 2 preprints · ORCID

ArticleLSD

Who Keeps Using Lysergic Acid Diethylamide? Correlates of Past-Year Use in People Who Initiated Use at least Five Years Ago.

Barnett BS, Anand A, Weleff J +2

Europe PMC2026
ArticleLSD

Perceived Availability of Lysergic Acid Diethylamide in the United States from 2015 to 2019.

Barnett BS, Anand A, Dewey EN +2

Europe PMC2026
ArticlePsilocybin

The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.

Weleff J, Pulido-Saavedra A, Aghaei AM +8

Europe PMC2025
ArticleKetamine

The contribution of psychotherapy in potential therapeutic effects of psychedelics for treatment of opioid use disorder.

Nia AB, Farahmand Y, Griffith G +4

Europe PMC2025
ArticleLSD

Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?

Barnett BS, Anand A, Dewey EN +4

Europe PMC2024
PreprintLSD

Perceived risk of LSD use in the United States from 2015-2019: Are Americans assessing LSD’s risk profile more favorably?

Barnett BS, Anand A, Dewey EN +3

Europe PMC2023
PreprintLSD

LSD use in the United States: Examining user demographics and their evolution from 2015-2019

Weleff J, Anand A, Dewey EN +1

Europe PMC2022